Saturday 17 October 2026
Export NYXH’s income statement to Excel — free account
Nyxoah SA
NYXH Healthcare Medical Instruments & Supplies
Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
1.11
0.08
−6.72%
Follow NYXH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 3 | 3 |
+8 more TTM periods Free account |
| (124.41%) | (138.78%) | (114.43%) | (106.55%) | ||
| (68.23%) | (75.37%) | (66.74%) | (70.17%) | ||
ROIC |
(117.82%) | (114.01%) | (122.99%) | (105.38%) | |
Return on Tangible Assets |
(138.39%) | (2,409.92%) | (552.43%) | (435.15%) | |
Average Days of Receivables |
174.00 | 216.82 | 271.86 | 285.75 | |
Free Cash Flow per Share |
(1.52) | (2.02) | (2.16) | (2.09) | |
Free Cash Flow |
(86.51) | (87.39) | (82.30) | (78.22) | |
Capital Expenditures |
(4.15) | (3.63) | (4.26) | (4.39) | |
| Other line items | |||||
Cash ROIC |
(30.96%) | (76.85%) | (52.55%) | (75.80%) | |
Accounts Receivable Turnover |
2.97 | 2.14 | 1.50 | 1.13 | |
Accounts Payable Turnover |
0.79 | 0.57 | 0.32 | 0.24 | |
Inventory Turnover |
1.93 | 1.35 | 0.81 | 0.35 | |
Average Days of Payables |
536.92 | 776.65 | 1,356.38 | 1,749.21 | |
Days of Inventory on Hand |
157.45 | 267.20 | 460.46 | 1,111.67 | |
Tax Rate |
0.02 | 0.02 | 0.01 | 0.03 | |
Research and Development Expense of Revenue |
195.25% | 278.87% | 427.39% | 774.65% | |
Selling, General and Administrative Expense of Revenue |
261.55% | 336.90% | 481.65% | 775.57% | |
Share Based Compensation of Revenue |
20.42% | 25.34% | 48.76% | 83.18% | |
Interest Coverage |
(4.39) | (8.83) | (7.25) | (10.78) | |
Operating CF/Net income |
0.74 | 0.86 | 0.77 | 0.81 | |
Depreciation/Fixed assets |
1.53 | 1.36 | 1.11 | 0.83 | |
Capex/Depreciation |
(0.56) | (0.58) | (0.84) | (1.08) | |
Revenue per Share |
0.44 | 0.41 | 0.30 | 0.16 | |
Operating CF per Share |
(1.44) | (1.94) | (2.05) | (1.97) | |
Capex per Share |
(0.07) | (0.08) | (0.11) | (0.12) | |
Capex to Sales |
0.17 | 0.21 | 0.38 | 0.71 |
Columns are period end dates